Shares of OptiNose (OPTN) have gained 58.6% over the past four weeks to close the last trading session at $9.15, but there could still be a solid upside left in the stock if short-term price ...

Critically ill patients with a high MELD score who were waitlisted for liver transplant at centers in low-population areas were more likely to die compared with patients listed in more populated ...

Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek Pharmaceuticals, a private biotech. This deal will add OPTN’s approved ...

March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial ...

Shares of OptiNose (NASDAQ:OPTN) climbed ~61% in the premarket on Thursday after the specialty pharmaceutical company agreed to be acquired by antibiotic drugmaker Paratek Pharmaceuticals in a ...

"We have fully cooperated with all regulatory agencies and swiftly implemented corrective actions after voluntarily pausing ...

The latest price target for (:OPTN) was reported by Piper Sandler on March 21, 2025. The analyst firm set a price target for $9.00 expecting OPTN to rise to within 12 months (a possible 0.22% upside).